Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Targeting Hsp90: small-molecule inhibitors and their clinical development.

Taldone T, Gozman A, Maharaj R, Chiosis G.

Curr Opin Pharmacol. 2008 Aug;8(4):370-4. doi: 10.1016/j.coph.2008.06.015. Epub 2008 Jul 31. Review.

2.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
3.

Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.

Kim T, Keum G, Pae AN.

Expert Opin Ther Pat. 2013 Aug;23(8):919-43. doi: 10.1517/13543776.2013.780597. Epub 2013 May 4. Review.

PMID:
23641970
4.

Inhibitors of the HSP90 molecular chaperone: current status.

Sharp S, Workman P.

Adv Cancer Res. 2006;95:323-48. Review.

PMID:
16860662
5.

Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.

Bhat R, Tummalapalli SR, Rotella DP.

J Med Chem. 2014 Nov 13;57(21):8718-28. doi: 10.1021/jm500823a. Epub 2014 Aug 29. Review.

PMID:
25141341
6.

Medicinal chemistry of Hsp90 inhibitors.

Drysdale MJ, Brough PA.

Curr Top Med Chem. 2008;8(10):859-68. Review.

PMID:
18673171
7.

Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).

Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G.

Ann N Y Acad Sci. 2006 Nov;1086:21-34. Review.

PMID:
17185503
8.

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.

Hanson BE, Vesole DH.

Expert Opin Investig Drugs. 2009 Sep;18(9):1375-83. doi: 10.1517/13543780903158934. Review.

PMID:
19642950
9.

Tanespimycin as antitumor therapy.

Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):17-22. doi: 10.3816/CLML.2011.n.002. Review.

PMID:
21454186
10.

Geldanamycin and its derivatives as Hsp90 inhibitors.

Gorska M, Popowska U, Sielicka-Dudzin A, Kuban-Jankowska A, Sawczuk W, Knap N, Cicero G, Wozniak F.

Front Biosci (Landmark Ed). 2012 Jun 1;17:2269-77. Review.

PMID:
22652777
11.

Structure-based and in silico design of Hsp90 inhibitors.

Sgobba M, Rastelli G.

ChemMedChem. 2009 Sep;4(9):1399-409. doi: 10.1002/cmdc.200900256. Review.

PMID:
19685544
12.

[Heat shock protein 90: novel target for cancer therapy].

Chen Y, Ding J.

Ai Zheng. 2004 Aug;23(8):968-74. Review. Chinese.

PMID:
15301726
13.

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.

Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC.

Br J Haematol. 2011 Feb;152(4):367-79. doi: 10.1111/j.1365-2141.2010.08360.x. Epub 2011 Jan 10. Review.

PMID:
21219297
14.

[Advances in antitumor activity of the hsp90 inhibitor geldanamycin].

Liao ZY, Zhen YS.

Yao Xue Xue Bao. 2001 Sep;36(9):716-20. Review. Chinese. No abstract available.

PMID:
12580116
16.

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

Chiosis G, Caldas Lopes E, Solit D.

Curr Opin Investig Drugs. 2006 Jun;7(6):534-41. Review.

PMID:
16784024
17.

Hsp90 molecular chaperone inhibitors: are we there yet?

Neckers L, Workman P.

Clin Cancer Res. 2012 Jan 1;18(1):64-76. doi: 10.1158/1078-0432.CCR-11-1000. Review.

18.

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.

Erlichman C.

Expert Opin Investig Drugs. 2009 Jun;18(6):861-8. doi: 10.1517/13543780902953699. Review.

PMID:
19466875
19.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Powers MV, Workman P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. Review.

20.

Hsp90: an emerging target for breast cancer therapy.

Beliakoff J, Whitesell L.

Anticancer Drugs. 2004 Aug;15(7):651-62. Review.

PMID:
15269596

Supplemental Content

Support Center